OREANDA-NEWS First Deputy General Director of the Nanolek pharmaceutical company, which is an industrial partner of the developer of the KoviVak vaccine - the Center named after. Chumakov, Maxim Stetsyuk said that the company stopped the production of the vaccine due to the lack of demand for it from the Ministry of Health of the Russian Federation. It is reported by TASS.

He stressed that Nanolek independently produced about 500,000 doses of KoviVak. At the moment, this batch is in the company's warehouse.

“Since December 2021, there have been no applications from the Ministry of Health for the supply of a vaccine, the company has not shipped a single dose of CoviVac,” Stetsyuk said.

According to him, together with the Chumakov Estate Center, about two million doses of the vaccine were produced, which are available.

The press service of the pharmacological company emphasized that the line, where KoviVac was previously produced, is currently producing Nanolek's own products, for example, a polio vaccine.

Earlier it became known that on May 4, the Russian Ministry of Health registered a new coronavirus drug, Mirobivir, based on a combination of nirmatrelvir and ritonavir.